FDA shake-up clears path for Huntington’s gene therapy AMT-130
TL;DR
UniQure’s Huntington’s disease gene therapy AMT-130 is back on track for FDA accelerated approval after the ouster of Vinay Prasad and other Trump-era regulators; the agency now accepts a standard-care control arm instead of sham surgeries, with a filing anticipated in Q3.
- "Truly evil" FDA rejection of gene therapy overturned after Trump official ousted Ars Technica
- Why Biotech Stocks Are Celebrating This Nail-Biter Investor's Business Daily
- UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy Bloomberg.com
- uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE) Seeking Alpha
- UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency CNBC
Want the full story? Read the original reporting
Read on Ars Technica